files/journal/2022-09-03_18-51-40-000000_599.png

Research Journal of Medical Sciences

ISSN: Online 1993-6095
ISSN: Print 1815-9346
About US
Editors
Issues
Pages
Indexed in
110
Views
19
Downloads

Low Molecular Weight Heparin in the Treatment of Severe Acute Pancreatitis: A Prospective Clinical Study

Chandrashekar B. Kerudi, V.R. AnilKumar, Sreekar Agumbe Pai and Anupama K. Pujar
Page: 448-452 | Received 20 Jan 2024, Accepted 03 Mar 2024, Published online: 05 Mar 2024

Download Citation
https://doi.org/10.36478/10.59218/makrjms.2024.5.448.452

Full Text Reference XML File PDF File

Abstract

Acute pancreatitis is a disease that has many aetiologies. Each aetiology seems to affect the pancreatic acinar cell in some way that results in premature activation and retention of potent proteolytic enzymes. Severe acute pancreatitis (SAP) is frequently a lethal disorder. Its mortality rate reaches up to 25‐40%. SAP is usually complicated with systemic inflammatory cascades and microcirculatory disturbance‐related morbidity due to infected pre pancreatic necrosis. Our objective was to study the effect of low molecular weight heparin (LMWH) in the treatment of severe acute pancreatitis (SAP). A total of 60 severe acute pancreatitis patients admitted to the hospital (MSRMTH) from September 2010 to October 2018 were included in the study. Necessary data was collected. 30 patients were grouped as control (A) and 30 patients as a test (LT). A group treated as conventional method and an LT group were given LMWH with conventional treatment. And comparison was done between the two groups. Patients satisfying the inclusion criteria were enrolled after taking informed consent and were assigned into 2 groups by random number table. Group A patients underwent conventional therapy including management of shock, maintenance of water and electrolytes balance, fasting, gastrointestinal decompression, administration of pancreatic enzymes inhibitor (Sandostatin), antibiotics (cephalosporins and metronidazole) and oral magnesium sulfate and symptomatic treatment. Group B patients received conventional therapy plus 100 mcg/kg/day of subcutaneous LMWH from the admission day and continued for 7 days. The mean age of presentation was 39‐45 years. 50% of the patients were aged between 30 and 50 years in both groups. The male population was around 80% in each study group. Improvement in the clinical symptoms in both the controls and cases were equal to 96.7%. LMWH is a simple, safe, economic and effective method for the treatment of SAP. It can be used in every hospital. Renal complications were more common among the cases as compared to complications related to sepsis among the control group. However, it was statistically not significant. The incidence of organ failure was slightly more but not statistically significant amongst the cases. However, larger human trials need to be conducted to evaluate the beneficial use.

How to cite this article:

Chandrashekar B. Kerudi, V.R. AnilKumar, Sreekar Agumbe Pai and Anupama K. Pujar. Low Molecular Weight Heparin in the Treatment of Severe Acute Pancreatitis: A Prospective Clinical Study.
DOI: https://doi.org/10.36478/10.59218/makrjms.2024.5.448.452
URL: https://www.makhillpublications.co/view-article/1815-9346/10.59218/makrjms.2024.5.448.452